Anne Wojcicki, the CEO and a co-founder of 23andMe, tells Nature's Soapbox Science blog that her company is moving toward working with pharmaceutical companies on phase 4, post-marketing studies. The company's database contains data from about 150,000 customers, the blog adds. "We definitely want to connect more and more with pharma partners to leverage the platform we've created," Wojcicki says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.